{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:51:17Z","timestamp":1780318277650,"version":"3.54.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>High tumour mutational burden (TMB-high), identified through comprehensive genomic profiling (CGP), is a biomarker that predicts the efficacy of immune checkpoint inhibitors. CGP testing is recommended for rare cancers with limited effective treatment options. Here, we provide the first report of a malignant phyllodes tumour of the breast demonstrating TMB-high status and effective treatment with pembrolizumab. The patient initially underwent right breast tumour resection and was diagnosed with a malignant phyllodes tumour. Recurrence was observed at the same site with metastases to the pulmonary hilar and right axillary lymph nodes. CGP testing revealed TMB-high status and microsatellite stable. Pembrolizumab was initiated after chemotherapy for the soft tissue sarcoma. After two treatment cycles, imaging revealed a partial response of the pulmonary hilar lymph nodes and necrotic enlargement of the right axillary lymph node. After four cycles, all lymph nodes had reduced in size. Eight months after ten cycles of pembrolizumab treatment, multiple new nodules were observed in both lungs, indicating disease progression. This case highlights the utility of CGP testing in rare cancers, demonstrating the first evidence of TMB-high malignant phyllodes tumours of the breast responding to pembrolizumab and underscoring the value of expanding CGP testing to improve therapeutic strategies for rare cancers.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1549452","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:31:06Z","timestamp":1740378666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case report: Efficacy of immune checkpoint inhibitors for high tumour mutational burden malignant phyllodes tumours of the breast as revealed by comprehensive genomic profiling"],"prefix":"10.3389","volume":"16","author":[{"given":"Hiroo","family":"Katsuya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Mihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Sci (New York NY)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00084","article-title":"Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data","volume":"2017","author":"Middha","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI Insight"},{"key":"B6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s40425-019-0647-4","article-title":"Tumor mutational burden quantification from targeted gene panels: major advancements and challenges","volume":"7","author":"Fancello","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22733","article-title":"Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions","volume":"58","author":"Stenzinger","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960301)77:5<910::AID-CNCR16>3.0.CO;2-6","article-title":"The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases","volume":"77","author":"Reinfuss","year":"1996","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/000313480006600408","article-title":"Phyllodes tumors of the breast: a review of 32 cases","volume":"66","author":"Geisler","year":"2000","journal-title":"Am Surgeon"},{"key":"B10","volume-title":"World Health Organization Classification of Tumours of the Breast","author":"Lakhani","year":"2012"},{"key":"B11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4274\/ejbh.galenos.2023.2023-3-2","article-title":"Management and outcomes of metastatic and recurrent Malignant phyllodes tumors of the breast: A systematic literature review","volume":"19","author":"Samii","year":"2023","journal-title":"Eur J Breast Health"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3409","article-title":"Genomic landscapes of breast fibroepithelial tumors","volume":"47","author":"Tan","year":"2015","journal-title":"Nat Genet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10549-017-4156-1","article-title":"Comprehensive genomic profiling of Malignant phyllodes tumors of the breast","volume":"162","author":"Nozad","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60111898","article-title":"Genomic analysis of advanced phyllodes tumors using next-generation sequencing and their chemotherapy response: A retrospective study using the C-CAT database","volume":"60","author":"Suzuki","year":"2024","journal-title":"Med (Kaunas Lithuania)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae218","article-title":"Genomic landscape of Malignant phyllodes tumors reveals multiple targetable opportunities","volume":"29","author":"Rosenberger","year":"2024","journal-title":"Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"631483","DOI":"10.3389\/fimmu.2021.631483","article-title":"Comprehensive genomic profiling of rare tumors in China: routes to immunotherapy","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-08097-x","article-title":"Impact of metastasis surgery and alkylating-agent-based chemotherapy on outcomes of metastatic Malignant phyllodes tumors: A multicenter retrospective study","volume":"27","author":"Neron","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00702","article-title":"Pembrolizumab in patients with tumors with high tumor mutational burden: results from the targeted agent and profiling utilization registry study","volume":"41","author":"Duvivier","year":"2023","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.molcel.2020.05.012","article-title":"POLE mutation spectra are shaped by the mutant allele identity, its abundance, and mismatch repair status","volume":"78","author":"Hodel","year":"2020","journal-title":"Mol Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1090838","DOI":"10.3389\/fimmu.2023.1090838","article-title":"Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/07357907.2024.2388107","article-title":"The landscape and prognosis of microsatellite stable (MSS) esophageal, gastro-esophageal junction and gastric adenocarcinomas with high tumor mutation burden (TMB)","volume":"42","author":"Voutsadakis","year":"2024","journal-title":"Cancer Invest"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1549452\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:31:08Z","timestamp":1740378668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1549452\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2025.1549452"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1549452","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"article-number":"1549452"}}